Target intelligence / Profile preview

Conserved oligomeric Golgi complex subunit 1 (COG1)

Target
COG1
Molecular classification
Other (Golgi-localized multisubunit tethering complex subunit), Peripheral membrane protein (not an enzyme, receptor, transporter, or transcription factor; does not have transmembrane domain), Part of a larger complex—the conserved oligomeric Golgi (COG) complex
01

Overview

Conserved oligomeric Golgi complex subunit 1 (**COG1**) is one of eight subunits forming the conserved oligomeric Golgi (COG) complex, a peripheral protein assembly crucial for maintaining normal Golgi morphology, trafficking, and glycosylation function in eukaryotic cells[1][2][4][5][6][7]. COG1 is a member of lobe A of the complex and acts both as a structural scaffold and as a key mediator of retrograde vesicle tethering—enabling proper recycling and localization of Golgi-resident glycosylation enzymes and other proteins[1][2][3][5]. Mutations disrupting COG1 function destabilize the complex and impair Golgi enzyme targeting, resulting in combined defects of N- and O-linked glycosylation and leading to congenital disorders of glycosylation (CDG)[2][3][5][6]. Though critical for Golgi and cellular homeostasis, COG1 is not an enzyme, receptor, or transporter, and has no direct therapeutic ligands; disease is associated solely with loss-of-function and structural instability[1][2][3][4][5][6][7].

Other names
Component of oligomeric Golgi complex 1COG1KIAA1381LDLBCOG complex subunit 1CDG2GLow density lipoprotein receptor defect B complementing
02

Mechanism of action

Not applicable (no drugs directly targeting COG1)

03

Biological functions

Golgi apparatus organization and morphology maintenanceRetrograde vesicle tethering in intra-Golgi traffickingRegulation and localization of Golgi glycosylation enzymesGlycoprotein processing, including steps in N- and O-linked glycosylation
04

Disease associations

Congenital disorders of glycosylation (CDG, specifically type IIg/CDG2G)Multisystem developmental abnormalities secondary to glycosylation defects
05

Safety considerations

Not applicable; COG1 is not a current drug target, but loss-of-function mutations cause significant pathophysiology (CDG syndromes)
06

Biomarkers

Glycosylation abnormalities detectable via reduced sialic acid and galactose residues in glycoproteins (serum analysis)Peanut agglutinin (PNA) lectin staining for O-glycan sialic acid contentAberrant Golgi morphology on cellular imaging

Beyond the preview

Go deeper on Conserved oligomeric Golgi complex subunit 1 (COG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conserved oligomeric Golgi complex subunit 1 (COG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call